Prompt follow-up

Breast cancerTriple-negative breast cancer

“Triple-negative” usually means the cancer is negative (or not strongly positive) for estrogen and progesterone receptors, and is HER2-negative by standard testing. Chemotherapy is often a key part of treatment in many people with invasive disease; immunotherapy and other options may be appropriate in selected early-stage or metastatic settings based on current criteria, testing, and your care team’s recommendations.

This page is for education only. It does not replace a visit with a qualified clinician. Your care team’s advice for you may differ from what you read here.

Preview — not yet published

This page is in editorial and medical review. Content below is a scaffold — treat it as a preview, not guidance.

Orientation

What to do next

A simple timeline many people find useful — your team’s pace may be faster or slower.

  1. Today

    Confirm the pathology and receptor testing are complete, including whether additional stains or a second look at a borderline result are needed.

  2. This week

    Expect discussions about stage, the role of chemotherapy, genetic counseling or testing when appropriate, and in selected situations immunotherapy or clinical trials.

  3. Over the next few weeks

    A treatment calendar often takes shape for early disease (surgery, chemo, radiation) or, for advanced disease, starting systemic treatment with a plan to reassess with imaging or exams.

Decisions ahead

Results that often matter for next steps

  • Receptor and HER2 status

    Negative/weak for ER/PR, HER2 not overexpressed (by IHC/ISH per lab)

    Triple-negative is defined by the absence of targetable hormone and HER2 markers on standard tests; the exact cutoff can vary slightly by lab, so you should know what the report actually says.

    Ask: Can I see the numbers or wording for ER, PR, and HER2 on the report?

  • BRCA and other risk genes (sometimes)

    Germline testing in selected patients, tumor testing in other settings

    Inherited BRCA mutations and other risk genes can affect treatment options, trial eligibility, and family members’ screening. Who is offered testing depends on age, family history, ancestry, tumor features, and guideline criteria.

    Ask: Is genetic or tumor-based testing right for me, and what are we looking for?

  • Stage, PD-L1, and (when useful) other markers

    Guides neoadjuvant therapy, advanced-line options, and trial eligibility in some cases

    In selected early-stage or metastatic settings, PD-L1 and other results may be used to help decide whether immunotherapy or other targeted approaches are appropriate. Not everyone needs every test; your team will follow current evidence and local availability.

    Ask: For my stage, what tests are still needed before we finalize the plan?

Treatment overview

Treatment by situation — not personal advice

Your care team tailors a plan to your specific stage, other health conditions, and preferences.

  • Early triple-negative (operative candidate)

    Common options
    Surgery, chemotherapy in many (not all) situations, and radiation as indicated. Neoadjuvant therapy may be used when appropriate and can inform next steps if surgery happens later.
    Why this may come up
    Pathologic response to preoperative treatment can be meaningful for some patients; the exact sequence and drugs depend on the tumor and the center.
    Questions to ask
    Is neoadjuvant therapy recommended, and if so, what is the plan if the tumor does not fully respond?

  • Metastatic triple-negative

    Common options
    Sequential chemotherapy, immunotherapy in selected eligible settings, targeted options when a matching biomarker is found, and clinical trials when appropriate. Goals of care and support services are part of the conversation.
    Why this may come up
    The disease is heterogeneous; the plan often evolves as you move through lines of treatment or enter trials.
    Questions to ask
    What are my standard options in order, and when is a second opinion or trial center reasonable?

Research

Clinical trials and when to ask (triple-negative)

Many trials in triple-negative disease focus on chemotherapy combinations, immunotherapy, targeted agents, or new approaches after earlier lines. Ask early: after diagnosis, before a first metastatic line, or at progression, depending on the study. Eligibility criteria and standard-care options are different for everyone.

When to seek care

Emergency, prompt, and routine

Call 911 or seek emergency care if

  • Sudden shortness of breath, severe headache, or confusion — seek emergency care as appropriate

Call your care team promptly if

  • Fever, chills, or new infection symptoms during or soon after treatment — follow the fever rule your team gave you

Bring this up at your next visit if

  • Fertility, menopause, and long-term health around chemotherapy
  • Palliative care or supportive services — often helpful, not only at end of life

For your next visit

Questions to ask your care team

  • How was triple-negative status confirmed, and is there any reason to recheck a borderline?

  • Should I have genetic counseling or inherited-risk testing, and could results affect treatment or family screening?

  • What is our plan for neoadjuvant vs surgery first, and why?

  • What trials do you know of that I might be eligible for at this stage?

  • What is the expected sequence if this treatment stops working?

Review, sources, and disclaimer

How this page was reviewed

Medical review

Pending medical review. This page will list the reviewing clinician and review date before publication.

Content version 0.1

This page is educational, not medical advice. Talk with your care team about decisions that apply to you. If something feels urgent, contact your doctor — or, for emergencies, call your local emergency number.